Biologic therapy of rheumatoid arthritis
Rheumatoid arthritis (RA) and juvenile idiopathic/rheumatoid arthritis (JIA) are chronic, inflammatory, systemic, auto-immune diseases characterized by chronic arthritis leading to progressive joint erosions. The individual functional and social impact of rheumatoid arthritis is of great importance....
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Serbian Medical Society
2009-01-01
|
| Series: | Srpski Arhiv za Celokupno Lekarstvo |
| Subjects: | |
| Online Access: | http://www.doiserbia.nb.rs/img/doi/0370-8179/2009/0370-81790904205D.pdf |
| _version_ | 1828931220555169792 |
|---|---|
| author | Damjanov Nemanja Vojinović Jelena |
| author_facet | Damjanov Nemanja Vojinović Jelena |
| author_sort | Damjanov Nemanja |
| collection | DOAJ |
| description | Rheumatoid arthritis (RA) and juvenile idiopathic/rheumatoid arthritis (JIA) are chronic, inflammatory, systemic, auto-immune diseases characterized by chronic arthritis leading to progressive joint erosions. The individual functional and social impact of rheumatoid arthritis is of great importance. Disability and joint damage occur rapidly and early in the course of the disease. The remarkably improved outcomes have been achieved initiating biologic therapy with close monitoring of disease progression. Biologic agents are drugs, usually proteins, which can influence chronic immune dysregulation resulting in chronic arthritis. According to the mechanism of action these drugs include: 1) anti-TNF drugs (etanercept, infiximab, adalimumab); 2) IL-1 blocking drugs (anakinra); 3) IL-6 blocking drugs (tocilizumab); 4) agents blocking selective co-stimulation modulation (abatacept); 5) CD 20 blocking drugs (rituximab). Biologics targeting TNF-alpha with methotrexate have revolutionized the treatment of RA, producing significant improvement in clinical, radiographic, and functional outcomes not seen previously. The new concept of rheumatoid arthritis treatment defines early diagnosis, early aggressive therapy with optimal doses of disease modifying antirheumatic drugs (DMARDs) and, if no improvement has been achieved during six months, early introduction of biologic drugs. The three-year experience of biologic therapy in Serbia has shown a positive effect on disease outcome. |
| first_indexed | 2024-12-14T00:43:32Z |
| format | Article |
| id | doaj.art-0c87cbc2393448f5b5507192a0ba78b9 |
| institution | Directory Open Access Journal |
| issn | 0370-8179 |
| language | English |
| last_indexed | 2024-12-14T00:43:32Z |
| publishDate | 2009-01-01 |
| publisher | Serbian Medical Society |
| record_format | Article |
| series | Srpski Arhiv za Celokupno Lekarstvo |
| spelling | doaj.art-0c87cbc2393448f5b5507192a0ba78b92022-12-21T23:24:13ZengSerbian Medical SocietySrpski Arhiv za Celokupno Lekarstvo0370-81792009-01-011373-420521010.2298/SARH0904205DBiologic therapy of rheumatoid arthritisDamjanov NemanjaVojinović JelenaRheumatoid arthritis (RA) and juvenile idiopathic/rheumatoid arthritis (JIA) are chronic, inflammatory, systemic, auto-immune diseases characterized by chronic arthritis leading to progressive joint erosions. The individual functional and social impact of rheumatoid arthritis is of great importance. Disability and joint damage occur rapidly and early in the course of the disease. The remarkably improved outcomes have been achieved initiating biologic therapy with close monitoring of disease progression. Biologic agents are drugs, usually proteins, which can influence chronic immune dysregulation resulting in chronic arthritis. According to the mechanism of action these drugs include: 1) anti-TNF drugs (etanercept, infiximab, adalimumab); 2) IL-1 blocking drugs (anakinra); 3) IL-6 blocking drugs (tocilizumab); 4) agents blocking selective co-stimulation modulation (abatacept); 5) CD 20 blocking drugs (rituximab). Biologics targeting TNF-alpha with methotrexate have revolutionized the treatment of RA, producing significant improvement in clinical, radiographic, and functional outcomes not seen previously. The new concept of rheumatoid arthritis treatment defines early diagnosis, early aggressive therapy with optimal doses of disease modifying antirheumatic drugs (DMARDs) and, if no improvement has been achieved during six months, early introduction of biologic drugs. The three-year experience of biologic therapy in Serbia has shown a positive effect on disease outcome.http://www.doiserbia.nb.rs/img/doi/0370-8179/2009/0370-81790904205D.pdfrheumatoid arthritisjuvenile idiopathic arthritisbiologic therapy |
| spellingShingle | Damjanov Nemanja Vojinović Jelena Biologic therapy of rheumatoid arthritis Srpski Arhiv za Celokupno Lekarstvo rheumatoid arthritis juvenile idiopathic arthritis biologic therapy |
| title | Biologic therapy of rheumatoid arthritis |
| title_full | Biologic therapy of rheumatoid arthritis |
| title_fullStr | Biologic therapy of rheumatoid arthritis |
| title_full_unstemmed | Biologic therapy of rheumatoid arthritis |
| title_short | Biologic therapy of rheumatoid arthritis |
| title_sort | biologic therapy of rheumatoid arthritis |
| topic | rheumatoid arthritis juvenile idiopathic arthritis biologic therapy |
| url | http://www.doiserbia.nb.rs/img/doi/0370-8179/2009/0370-81790904205D.pdf |
| work_keys_str_mv | AT damjanovnemanja biologictherapyofrheumatoidarthritis AT vojinovicjelena biologictherapyofrheumatoidarthritis |